Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON)
Non Interventional Study Dealing With the Use of Trabectedin (Yondelis®)-Pegylated Liposomal Doxorubicin (Caelyx®) in Patient With Platinum-sensitive Relapse
Sponsor: ARCAGY/ GINECO GROUP
This observational or N/A phase trial investigates Ovarian Cancer and is currently completed. ARCAGY/ GINECO GROUP leads this study, which shows 11 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Oct 2020 — Jan 2021 [monthly]
Completed
▶ Show 6 earlier versions
-
Dec 2018 — Oct 2020 [monthly]
Completed
Status: Unknown Status → Completed
-
Jul 2018 — Dec 2018 [monthly]
Unknown Status
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting
Phase: NA → None
-
Sep 2017 — Apr 2018 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Sep 2017 [monthly]
Active Not Recruiting NA
First recorded
Jul 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ARCAGY/ GINECO GROUP
- PharmaMar
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Agen, France , Amiens, France , Angers, France , Bayonne, France , Besançon, France , Bordeaux, France , Bourg-en-Bresse, France , Brest, France , Chalon-sur-Saône, France , Cholet, France and 21 more locations